These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 16362261)
21. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer. Jean GW; Shah SR Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402 [TBL] [Abstract][Full Text] [Related]
23. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer. Herbst RS; Hong WK Semin Oncol; 2002 Oct; 29(5 Suppl 14):18-30. PubMed ID: 12422310 [TBL] [Abstract][Full Text] [Related]
24. Epidermal growth factor receptor inhibitors in colorectal cancer: it's time to get back on target. Meropol NJ J Clin Oncol; 2005 Mar; 23(9):1791-3. PubMed ID: 15677698 [No Abstract] [Full Text] [Related]
25. Anti-EGFR monoclonal antibodies for treatment of colorectal cancers: development of cetuximab and panitumumab. You B; Chen EX J Clin Pharmacol; 2012 Feb; 52(2):128-55. PubMed ID: 21427284 [TBL] [Abstract][Full Text] [Related]
26. Clinical research of EGFR inhibitors and related dermatologic toxicities. Perez-Soler R; Van Cutsem E Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):10-6. PubMed ID: 18154213 [TBL] [Abstract][Full Text] [Related]
30. Epidermal growth factor receptor as a target for chemotherapy. Vallbohmer D; Lenz HJ Clin Colorectal Cancer; 2005 Apr; 5 Suppl 1():S19-27. PubMed ID: 15871762 [TBL] [Abstract][Full Text] [Related]
31. Cetuximab-associated elongation of the eyelashes: case report and review of eyelash trichomegaly secondary to epidermal growth factor receptor inhibitors. Cohen PR; Escudier SM; Kurzrock R Am J Clin Dermatol; 2011 Feb; 12(1):63-7. PubMed ID: 20726623 [TBL] [Abstract][Full Text] [Related]
33. Association between serum ligands and the skin toxicity of anti-epidermal growth factor receptor antibody in metastatic colorectal cancer. Takahashi N; Yamada Y; Furuta K; Nagashima K; Kubo A; Sasaki Y; Shoji H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Hamaguchi T; Shimada Y Cancer Sci; 2015 May; 106(5):604-10. PubMed ID: 25707609 [TBL] [Abstract][Full Text] [Related]
34. Best practices in the management of toxicities related to anti-EGFR agents for metastatic colorectal cancer. Ouwerkerk J; Boers-Doets C Eur J Oncol Nurs; 2010 Sep; 14(4):337-49. PubMed ID: 20580896 [TBL] [Abstract][Full Text] [Related]
35. Treatment of unresectable squamous cell carcinoma of the skin with epidermal growth factor receptor antibodies--a case series. Eder J; Simonitsch-Klupp I; Trautinger F Eur J Dermatol; 2013; 23(5):658-62. PubMed ID: 24135559 [TBL] [Abstract][Full Text] [Related]
36. Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. Hu JC; Sadeghi P; Pinter-Brown LC; Yashar S; Chiu MW J Am Acad Dermatol; 2007 Feb; 56(2):317-26. PubMed ID: 17141360 [TBL] [Abstract][Full Text] [Related]
37. Clinical use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer. Patel DK Pharmacotherapy; 2008 Nov; 28(11 Pt 2):31S-41S. PubMed ID: 18980550 [TBL] [Abstract][Full Text] [Related]
38. Treatment with panitumumab after a severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer: a case report. Heun J; Holen K Clin Colorectal Cancer; 2007 May; 6(7):529-31. PubMed ID: 17553202 [TBL] [Abstract][Full Text] [Related]
39. Cutaneous toxicity from epidermal growth factor receptor inhibitors: would a subcutaneous desensitization be helpful? Case report. D'Alessio A; Cecchini S; Di Mauro D; Geroli L; Villa S; Quadri A; Resta D; Fortugno C Tumori; 2016 Nov; 102(Suppl. 2):. PubMed ID: 27791234 [TBL] [Abstract][Full Text] [Related]